TY - JOUR
T1 - Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression
AU - Euler, Zelda
AU - Van Gils, Mařit J.
AU - Bunnik, Evelien M.
AU - Phung, Pham
AU - Schweighardt, Becky
AU - Wrin, Terri
AU - Schuitemaker, Hanneke
N1 - Funding Information:
Financial support: The Netherlands Organization for Scientific Research (grant 918.66.628), the Dutch AIDS fund (grant 2004064), the European Community’s Sixth Framework Programme EUROPRISE (FP6/2006-2011, under grant 037611), and the European Community’s Seventh Framework Programme NGIN (FP7/2007-2013, under grant 201433). The Amsterdam Cohort Studies on HIV infection and AIDS, a collaboration between the Amsterdam Health Service, the Academic Medical Center of the University of Amsterdam, Sanquin Blood Supply Foundation, the University Medical Center Utrecht, and the Jan van Goyen Clinic, are part of the Netherlands HIV Monitoring Foundation and financially supported by the Center for Infectious Disease Control of the Netherlands National Institute for Public Health and the Environment. a M.J.v.G. and E.M.B. contributed equally to this work.
PY - 2010/4/1
Y1 - 2010/4/1
N2 - Broadly reactive neutralizing antibodies are the focus of human immunodeficiency virus (HIV) type 1 vaccine design. However, only little is known about their role in acquired immunodeficiency syndrome (AIDS) pathogenesis and the factors associated with their development. Here we used a multisubtype panel of 23 HIV-1 variants to determine the prevalence of cross-reactive neutralizing activity in serum samples obtained ∼35 months after seroconversion from 82 HIV-1 subtype B-infected participants from the Amsterdam Cohort Studies on HIV Infection and AIDS. Of these patients, 33%, 48%, and 20%, respectively, had strong, moderate, or absent cross-reactive neutralizing activity in serum. Viral RNA load at set point and AIDS-free survival were similar for the 3 patient groups. However, higher cross-reactive neutralizing activity was significantly associated with lower CD4+ T cell counts before and soon after infection. Our findings underscore the importance of vaccine-elicited immunity in protecting from infection. The association between CD4+ T cell counts and neutralizing humoral immunity may provide new clues as to how to achieve this goal.
AB - Broadly reactive neutralizing antibodies are the focus of human immunodeficiency virus (HIV) type 1 vaccine design. However, only little is known about their role in acquired immunodeficiency syndrome (AIDS) pathogenesis and the factors associated with their development. Here we used a multisubtype panel of 23 HIV-1 variants to determine the prevalence of cross-reactive neutralizing activity in serum samples obtained ∼35 months after seroconversion from 82 HIV-1 subtype B-infected participants from the Amsterdam Cohort Studies on HIV Infection and AIDS. Of these patients, 33%, 48%, and 20%, respectively, had strong, moderate, or absent cross-reactive neutralizing activity in serum. Viral RNA load at set point and AIDS-free survival were similar for the 3 patient groups. However, higher cross-reactive neutralizing activity was significantly associated with lower CD4+ T cell counts before and soon after infection. Our findings underscore the importance of vaccine-elicited immunity in protecting from infection. The association between CD4+ T cell counts and neutralizing humoral immunity may provide new clues as to how to achieve this goal.
UR - http://www.scopus.com/inward/record.url?scp=77749306129&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77749306129&partnerID=8YFLogxK
U2 - 10.1086/651144
DO - 10.1086/651144
M3 - Article
C2 - 20170371
AN - SCOPUS:77749306129
SN - 0022-1899
VL - 201
SP - 1045
EP - 1053
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 7
ER -